EUVIMEDEUVIMED entdecken
Crossref

The Analysis of the FIX‐inhibitor Risks Associated With the F9 Genotype in Patients With Haemophilia B Exposes the Involvement of Nonsense Mediated‐Decay: Argentinean and International Series

Betiana Michelle Ziegler, Miguel Martín Abelleyro, María Emilia Villegas, Julián Sanchez Loria, Héctor Martín Cifuentes, Daniela Neme, Gabriela Sciuccati, Carolina Cervio, Verónica Arrieta, Viviana Listello, María Sol Cruz, María Gabriela Erro und 4 weitere

Haemophilia · 2026-11 · 32 (6) · 1488-1497

DOI: 10.1111/hae.70356 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, online erschienen am 20.07.2026. Verfasst von Betiana Michelle Ziegler und 15 weiteren Autor:innen. Beteiligte Einrichtung: Instituto De Medicina Experimental (IMEX), (CONICET-Academia Nacional de Medicina), Ciudad de Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Hemophilia B, Factor IX. Die Arbeit nennt 32 Literaturangaben. Gefördert von: National Research Council, Consiglio Nazionale delle Ricerche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Haemophilia B (HB) associates with deleterious variants in F9 . HB management with FIX‐concentrate infusions may be ineffective in 3%–9% patients who develop FIX‐inhibitors.

Aim

To present our HB‐series ( n = 136) including all Argentinean patients with FIX‐inhibitors ( n = 13). To estimate F9 ‐genotype‐associated FIX‐inhibitor risks from our series (GMH), and HB‐international databases, FIX‐UCL and EAHAD.

Methods

F9 ‐genotyping was performed by conventional protocols; or by short‐read‐NGS on a new F9 ‐panel. FIX‐inhibitor risks were estimated by case(inh+)/control(inh‐) studies using OR(95%CI).

Results

The spectrum of F9 ‐genotypes from our GMH‐series resulted similar to the one compiled in international databases, prevailing missense (45%), and nonsense (21%) in severe‐HB and missense defects (> 80%) in non‐severe‐HB. Our set of HB‐patients with FIX‐inhibitors mostly included large‐deletions and nonsense mutations, and 38.5% developed allergic reactions. Case/Control studies mainly aligned FIX‐inhibitor risks in all three datasets. Considering severe‐HB in GMH( n = 91)//FIX‐UCL( n = 349)//EAHAD( n = 590), we observed a high‐risk group that comprised entire‐ F9 ‐deletions with highly‐significant ORs of 24//12//35, all‐large‐deletions, 7//7//17 and nonsense mutations, 3//3//2; and a low‐risk group confined to missense F9 ‐variants with highly‐significant protective ORs, 0.04//0.11//0.03, whilst other F9 ‐variants did not differ from the null‐hypothesis. Equal analysis from all‐severities HB patients closely agreed with these results. An analysis of NS and FIX‐inhibitor risks suggested the involvement of nonsense‐mediated decay (NMD) in F9 : nonsense ( F9 ‐exons_1–7) vs nonsense ( F9 ‐exon_8) resulted in highly‐significantly incremented risks in both FIX‐UCL( n = 124)//EAHAD( n = 171), ORs of 4(2–9)//4(3–6).

Conclusion

Our study provides robust estimations of F9 ‐genotype‐associated FIX‐inhibitor risks in HB‐patients and exposed the involvement of NMD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia BFactor IXHumansGenotypeArgentinaAdolescentMaleChildAdultChild, PreschoolYoung AdultCodon, NonsenseMiddle AgedFemaleInfantRisk FactorsCase-Control Studies

Stichwörter der Autor:innen

FIX inhibitorscase‐control studyhaemophilia Bmolecular analysisnonsense mediated decay

Substanzen

Factor IXCodon, Nonsense

Autor:innen und Institutionen

  • Instituto De Medicina Experimental (IMEX), (CONICET-Academia Nacional de Medicina), Ciudad de Buenos Aires, Argentina.
  • Instituto De Investigaciones Hematológicas Mariano Castex (IIHEMA), (Academia Nacional de Medicina), Ciudad de Buenos Aires, Argentina.
  • Unidad Operativa Centro Nacional de Genómica y Bioinformática (UOCNGyB), Administración Nacional de Laboratorios e Institutos De Salud (ANLIS) "Dr. Carlos G. Malbrán", Ciudad de Buenos Aires, Argentina.
  • Unidad De Conocimiento Traslacional Hospitalaria Patagónica (UCTHP), Hospital de Alta Complejidad El Calafate SAMIC, Santa Cruz, El Calafate, Argentina.
  • Fundación de la Hemofilia Alfredo Pavlovsky, Ciudad de Buenos Aires, Argentina.
  • Hospital De Pediatría S.A.M.I.C. "Prof. Dr. Juan P. Garrahan", Ciudad de Buenos Aires, Argentina.

Förderung

  • National Research Council
  • Consiglio Nazionale delle Ricerche

Zitieren

APA

Ziegler, B. M., Abelleyro, M. M., Villegas, M. E., Loria, J. S., Cifuentes, H. M., Neme, D., Sciuccati, G., Cervio, C., Arrieta, V., Listello, V., Cruz, M. S., Erro, M. G., Sánchez-Luceros, A., De Brasi, C. D., Radic, C. P., & Rossetti, L. C. (2026). The Analysis of the FIX‐inhibitor Risks Associated With the F9 Genotype in Patients With Haemophilia B Exposes the Involvement of Nonsense Mediated‐Decay: Argentinean and International Series. Haemophilia, 32(6), 1488-1497. https://doi.org/10.1111/hae.70356

Vancouver

Ziegler BM, Abelleyro MM, Villegas ME, Loria JS, Cifuentes HM, Neme D, et al. The Analysis of the FIX‐inhibitor Risks Associated With the F9 Genotype in Patients With Haemophilia B Exposes the Involvement of Nonsense Mediated‐Decay: Argentinean and International Series. Haemophilia. 2026;32(6):1488-1497. doi:10.1111/hae.70356

BibTeX
@article{Ziegler2026,
  author = {Ziegler, Betiana Michelle and Abelleyro, Miguel Martín and Villegas, María Emilia and Loria, Julián Sanchez and Cifuentes, Héctor Martín and Neme, Daniela and Sciuccati, Gabriela and Cervio, Carolina and Arrieta, Verónica and Listello, Viviana and Cruz, María Sol and Erro, María Gabriela and Sánchez-Luceros, Analía and De Brasi, Carlos Daniel and Radic, Claudia Pamela and Rossetti, Liliana Carmen},
  title = {The Analysis of the FIX‐inhibitor Risks Associated With the F9 Genotype in Patients With Haemophilia B Exposes the Involvement of Nonsense Mediated‐Decay: Argentinean and International Series},
  journal = {Haemophilia},
  year = {2026},
  volume = {32},
  number = {6},
  pages = {1488--1497},
  doi = {10.1111/hae.70356}
}
Kostenlos starten →